In the News
Incorporating Real-world Evidence into the Life Cycle of Drug Development
Susan Oliveria discusses how and why RWD and RWE are making an important impact on the development of medicines.
Extractables & Leachables: Detecting the Unknown with E&L Analysis
The authors examine how a new generation of extraction, identification and quantification tools – now recognized as approved methods by regulatory bodies – is changing the E&L testing landscape.
Making Clinical Trials More Sustainable by Digitization and Decentralization
Michael Cohen comments on how digitizing, decentralizing and near-patient can reduce the environmental impact of clinical research.
Taking Steps to Right the Wrongs: The Impact of Racial Bias in Healthcare and Medicine
Rose Blackburne discusses the huge opportunity for continued innovations that bring research closer to patients to help address health inequities.
The ongoing evolution and implementation of DCTs in 2023
Jill Sommerville discusses the challenges, opportunities and evolution of decentralized clinical trials.
Complex analytical workflows increasingly require robust bioassays
Catherine Liloia and Benjamin Ziehr comment on the crucial role bioassays play in biologic drug development.
The 2023 PharmaVoice Year in Preview
Lisa Dyment and Lloryn Hubbard weigh in on key areas of industry focus, including patient engagement and clinical trial diversity, for 2023.
The value of predictive analytical applications as digital health tools
Thomas Healy discusses the emerging benefits and capabilities of predictive analytic applications supported by wearable sensor devices.
Enabling digital and decentralized solutions in clinical research
In this article, Kamilla Posselt outlines the importance of embedding digital and decentralized solutions during early trial development.
